{"protocolSection":{"identificationModule":{"nctId":"NCT07148414","orgStudyIdInfo":{"id":"SPY002-072-201"},"organization":{"fullName":"Spyre Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of SPY072 in Rheumatic Disease","officialTitle":"Phase 2 Study to Assess the Efficacy and Safety of SPY002-072 in Adults With Moderately to Severely Active Rheumatologic Disease","acronym":"SKYWAY-RD"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-08-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-10-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-03-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-08-21","studyFirstSubmitQcDate":"2025-08-21","studyFirstPostDateStruct":{"date":"2025-08-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-01","lastUpdatePostDateStruct":{"date":"2026-02-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Spyre Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).","detailedDescription":"The basket study comprises of substudies in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatric arthritis (PsA) as follows:\n\n* RA substudy: Moderately to severely active RA despite treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic disease modifying anti-rheumatic drugs (bDMARDs), or targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs)\n* axSpA substudy: Moderately to severely active axSpA despite treatment with non-steroidal anti-inflammatory drugs (NSAIDS), bDMARDs, or tsDMARDs\n* PsA substudy: Moderately to severely active PsA despite treatment with NSAIDs, csDMARDs, bDMARDs, or tsDMARDs"},"conditionsModule":{"conditions":["Rheumatoid Arthritis","Psoriatic Arthritis","Axial Spondyloarthritis","Rheumatic Diseases","Rheumatic Joint Disease","PsA (Psoriatic Arthritis)","AxSpA","Rheumatologic Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":285,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Rheumatoid Arthritis, Dose Regimen 1","type":"EXPERIMENTAL","description":"Participants will receive double-blind dosing regimen 1 of SPY072","interventionNames":["Drug: SPY002-072"]},{"label":"Rheumatoid Arthritis, Dose Regimen 2","type":"EXPERIMENTAL","description":"Participants will receive double-blind dosing regimen 2 of SPY072","interventionNames":["Drug: SPY002-072"]},{"label":"Psoriatic Arthritis","type":"EXPERIMENTAL","description":"Participants will receive double-blind dose of SPY072","interventionNames":["Drug: SPY002-072"]},{"label":"Axial Spondyloarthritis","type":"EXPERIMENTAL","description":"Participants will receive double-blind dose of SPY072","interventionNames":["Drug: SPY002-072"]},{"label":"Rhematoid Arthritis Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive matching placebo","interventionNames":["Drug: Placebo"]},{"label":"Psoriatic Arthritis Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive matching placebo","interventionNames":["Drug: Placebo"]},{"label":"Axial Spondyloarthritis Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive matching placebo","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"SPY002-072","description":"Experimental","armGroupLabels":["Axial Spondyloarthritis","Psoriatic Arthritis","Rheumatoid Arthritis, Dose Regimen 1","Rheumatoid Arthritis, Dose Regimen 2"],"otherNames":["SPY072"]},{"type":"DRUG","name":"Placebo","description":"Matching Placebo","armGroupLabels":["Axial Spondyloarthritis Placebo","Psoriatic Arthritis Placebo","Rhematoid Arthritis Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP)","description":"The score is calculated based on the number of tender and swollen joints out of 28 assessed (TJC28 and SJC28), a measure of inflammation in the blood (c-reactive protein, CRP), and the subject's overall assessment of their health (patient global assessment). Scores range from 0-10. Higher scores indicate greater disease activity.","timeFrame":"Week 12"},{"measure":"Axial Spondyloarthritis: Change from baseline in Ankylosing Spondylitis Disease Activity Score (ADAS)","description":"The score combines 5 disease activity variables (back pain, duration of morning stiffness, patient global assessment of disease activity, peripheral pain/swelling and measure of inflammation) to measure disease activity. Lowest score is 0.6 and increases as disease worsens. Higher scores indicate greater disease activity.","timeFrame":"Week 16"},{"measure":"Psoriatic Arthritis: Proportion of participants who achieve an American College of Rheumatology 20 Response Criteria (ACR20) response","description":"The proportion of subjects who achieve at least 20% improvement in tender and swollen joint counts (TJC and SJC), and at least 20% improvement in 3 out of 5 other disease activity measures (patient global assessment, physician global assessment, patient pain assessment, health assessment questionnaire, and measure of inflammation) will be assessed.","timeFrame":"Week 16"}],"secondaryOutcomes":[{"measure":"Rheumatoid Arthritis: Proportion of participants who achieve an ACR20 response","description":"The proportion of subjects who achieve at least 20% improvement in tender and swollen joint counts, and at least 20% improvement in 3 out of 5 other disease activity measures will be assessed.","timeFrame":"Week 12"},{"measure":"Axial Spondyloarthritis: Proportion of participants who achieve an Assessment of Spondyloarthritis International Society (40% improvement) (ASAS40) response","description":"The proportion of subjects who achieve at least 40% improvement in at least 3 out of 4 key domains related to disease severity (patient global assessment of disease activity, back pain, physical function, inflammation) while not experiencing worsening in the remain domain will be assessed.","timeFrame":"Week 16"},{"measure":"Psoriatic Arthritis: Change from baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA)","description":"The sum of 5 key disease variables (tender joint count, swollen joint count, patient pain assessment, patient global assessment of disease activity, and C-reactive protein) will be assessed. Scores range from 0.1 to 86. Higher score indicates higher disease activity.","timeFrame":"Week 16"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nFor rheumatoid arthritis:\n\n* Moderate-to-severely active RA as defined by the presence of ≥4 swollen joints (based on 28 joint count) and ≥4 tender joints (based on 28 joint count) at Screening and Day 1.\n* Documentation of ≥1 of the following:\n\n  1. Positive test results for rheumatoid factor or anti-citrullinated peptide antibodies at Screening, OR\n  2. Radiology report documenting bony erosions in hands or feet consistent with RA on previous radiographs\n* Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to:\n\n  1. ≥1 csDMARD treatment; AND/OR\n  2. ≤2 classes of bDMARD/tsDMARD treatment (\\>2 classes of bDMARDs and/or tsDMARDs is exclusionary)\n\nFor axial spondyloarthritis:\n\n* Moderate-to-severely active axSpA defined by BOTH of the following at Screening AND Day 1:\n\n  1. BASDAI ≥4, AND\n  2. Back pain ≥4 (from BASDAI Item 2)\n* hsCRP greater than the ULN per the central laboratory at Screening\n* Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to:\n\n  1. 2 different NSAIDs given at the maximum tolerated dose for ≥4 weeks or intolerant to or has a contraindication to NSAID therapy; AND/OR\n  2. ≤2 classes of bDMARD (anti-TNF or anti-IL-17)/tsDMARD at an approved dose for ≥12 weeks (\\>2 classes of bDMARDs/tsDMARDs is exclusionary)\n\nFor psoriatic arthritis:\n\n* Screening and Day 1 TJC ≥3 out of 68 and SJC ≥3 out of 66 (dactylitis counts as 1 joint each)\n* ≥1 active plaque psoriasis lesion and/or a documented history of psoriasis\n* Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to:\n\n  1. ≥1 NSAID treatment; AND\n  2. ≥1 csDMARD treatment; AND/OR ≤2 classes of bDMARD/tsDMARD treatment (\\>2 classes of bDMARDs and/or tsDMARDs is exclusionary)\n\nExclusion Criteria:\n\n* Inadequate response to \\>2 classes of bDMARDs/tsDMARDs\n* Other autoimmune, rheumatologic, inflammatory diseases or pain-amplification syndromes that might confound the evaluations of efficacy of SPY072","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT","phone":"+1-650-402-3164","email":"info@skyway-rd.com"}],"overallOfficials":[{"name":"SKYWAY-RD Study Director","affiliation":"Spyre Therapeutics","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Site 113","status":"RECRUITING","city":"Avondale","state":"Arizona","zip":"85392","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":33.4356,"lon":-112.3496}},{"facility":"Site 114","status":"RECRUITING","city":"Chula Vista","state":"California","zip":"91910","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":32.64005,"lon":-117.0842}},{"facility":"Site 111","status":"RECRUITING","city":"Covina","state":"California","zip":"91722","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":34.09001,"lon":-117.89034}},{"facility":"Site 108","status":"RECRUITING","city":"Tujunga","state":"California","zip":"91042","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":34.25223,"lon":-118.28841}},{"facility":"Site 112","status":"RECRUITING","city":"Upland","state":"California","zip":"91786","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":34.09751,"lon":-117.64839}},{"facility":"Site 107","status":"RECRUITING","city":"Whittier","state":"California","zip":"90602","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":33.97918,"lon":-118.03284}},{"facility":"Site 109","status":"RECRUITING","city":"Hialeah","state":"Florida","zip":"33016","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"Site 106","status":"RECRUITING","city":"Ormond Beach","state":"Florida","zip":"32174","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":29.28581,"lon":-81.05589}},{"facility":"Site 110","status":"RECRUITING","city":"Tampa","state":"Florida","zip":"33614","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Site 104","status":"RECRUITING","city":"Duncansville","state":"Pennsylvania","zip":"16635","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":40.42341,"lon":-78.4339}},{"facility":"Site 105","status":"RECRUITING","city":"Corpus Christi","state":"Texas","zip":"78404","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":27.80058,"lon":-97.39638}},{"facility":"Site 103","status":"RECRUITING","city":"Tomball","state":"Texas","zip":"77375","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":30.09716,"lon":-95.61605}},{"facility":"Site 102","status":"RECRUITING","city":"Tomball","state":"Texas","zip":"77377","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":30.09716,"lon":-95.61605}},{"facility":"Site 503","status":"RECRUITING","city":"Lovech","state":"Lovech","zip":"5500","country":"Bulgaria","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":43.13227,"lon":24.71763}},{"facility":"Site 502","status":"RECRUITING","city":"Pleven","state":"Pleven","zip":"5803","country":"Bulgaria","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":43.41791,"lon":24.61666}},{"facility":"Site 506","status":"RECRUITING","city":"Plovdiv","state":"Plovdiv","zip":"4000","country":"Bulgaria","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":42.15387,"lon":24.75001}},{"facility":"Site 505","status":"RECRUITING","city":"Plovdiv","state":"Plovdiv","zip":"4003","country":"Bulgaria","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":42.15387,"lon":24.75001}},{"facility":"Site 504","status":"RECRUITING","city":"Varna","state":"Varna","zip":"9000","country":"Bulgaria","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":43.21912,"lon":27.91024}},{"facility":"Site 706","status":"RECRUITING","city":"Hlučín","state":"Hlučín","zip":"748 01","country":"Czechia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":49.89795,"lon":18.19196}},{"facility":"Site 702","status":"RECRUITING","city":"Moravská Ostrava","state":"Ostrava-město","zip":"702 00","country":"Czechia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":49.84249,"lon":18.26727}},{"facility":"Site 704","status":"RECRUITING","city":"Pardubice","state":"Pardubický kraj","zip":"530 02","country":"Czechia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":50.04075,"lon":15.77659}},{"facility":"Site 705","status":"RECRUITING","city":"Prague","state":"Praha, Hlavní Mesto","zip":"130 00","country":"Czechia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Site 303","status":"RECRUITING","city":"Tbilisi","state":"K'alak'i T'bilisi","zip":"0102","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 304","status":"RECRUITING","city":"Tbilisi","state":"K'alak'i T'bilisi","zip":"0112","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 301","status":"RECRUITING","city":"Tbilisi","state":"K'alak'i T'bilisi","zip":"0159","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 307","status":"RECRUITING","city":"Tbilisi","state":"K'alak'i T'bilisi","zip":"0172","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 305","status":"RECRUITING","city":"Tbilisi","state":"K'alak'i T'bilisi","zip":"0186","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 308","status":"RECRUITING","city":"Batumi","zip":"6010","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.64077,"lon":41.6306}},{"facility":"Site 302","status":"RECRUITING","city":"Kutaisi","zip":"4600","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":42.26791,"lon":42.69459}},{"facility":"Site 306","status":"RECRUITING","city":"Tbilisi","zip":"0186","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 201","status":"RECRUITING","city":"Chisinau","zip":"MD-2025","country":"Moldova","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":47.00902,"lon":28.85938}},{"facility":"Site 202","status":"RECRUITING","city":"Chisinau","zip":"MD-2025","country":"Moldova","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":47.00902,"lon":28.85938}},{"facility":"Site 401","status":"RECRUITING","city":"Krakow","state":"Lesser Poland Voivodeship","zip":"30-363","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Site 407","status":"RECRUITING","city":"Nowa Sól","state":"Lubusz Voivodeship","zip":"67-100","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":51.80333,"lon":15.71702}},{"facility":"Site 403","status":"RECRUITING","city":"Warsaw","state":"Masovian Voivodeship","zip":"02-677","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Site 402","status":"RECRUITING","city":"Opole","state":"Opole Voivodeship","zip":"45-819","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":50.67119,"lon":17.92604}},{"facility":"Site 406","status":"RECRUITING","city":"Gdynia","state":"Pomeranian Voivodeship","zip":"81-384","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":54.51889,"lon":18.53188}},{"facility":"Site 405","status":"RECRUITING","city":"Warszawa","state":"Pomeranian Voivodeship","zip":"00-874","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}]},{"facility":"Site 408","status":"RECRUITING","city":"Elblag","state":"Warmian-Masurian Voivodeship","zip":"82-300","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":54.1522,"lon":19.40884}},{"facility":"Site 602","status":"RECRUITING","city":"A Coruña","state":"A Coruña","zip":"15006","country":"Spain","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Site 604","status":"RECRUITING","city":"Chiclana de la Frontera","state":"Cadiz","zip":"11139","country":"Spain","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":36.41976,"lon":-6.14367}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D001172","term":"Arthritis, Rheumatoid"},{"id":"D015535","term":"Arthritis, Psoriatic"},{"id":"D000089183","term":"Axial Spondyloarthritis"},{"id":"D012216","term":"Rheumatic Diseases"},{"id":"D003095","term":"Collagen Diseases"}],"ancestors":[{"id":"D001168","term":"Arthritis"},{"id":"D007592","term":"Joint Diseases"},{"id":"D009140","term":"Musculoskeletal Diseases"},{"id":"D003240","term":"Connective Tissue Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D007154","term":"Immune System Diseases"},{"id":"D025242","term":"Spondylarthropathies"},{"id":"D025241","term":"Spondylarthritis"},{"id":"D013166","term":"Spondylitis"},{"id":"D013122","term":"Spinal Diseases"},{"id":"D001847","term":"Bone Diseases"},{"id":"D011565","term":"Psoriasis"},{"id":"D017444","term":"Skin Diseases, Papulosquamous"},{"id":"D012871","term":"Skin Diseases"},{"id":"D000844","term":"Ankylosis"}]}},"hasResults":false}